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Abstract
The present scientiﬁc opinion deals with the evaluation of the safety of di-magnesium malate (DMM)
proposed as a novel food ingredient and as a source of magnesium for use in foods for the general
population, food supplements, total diet replacement for weight control and food for special medical
purposes (FSMP), and with the bioavailability of magnesium from this source. Additional information
was sought from the applicant during the assessment process. However, despite several requests, the
applicant did not provide the additional data. Consequently, the Panel performed this assessment on
the basis of the available data and concluded that there was insufﬁcient scientiﬁc evidence of a
difference between the proposed novel food ingredient named as DMM and magnesium malate already
authorised as a source of magnesium included in Annex II to Directive 2002/46/EC. Accordingly, the
Panel was unable to assess the safety of DMM as a novel food ingredient. The Panel concluded that
based on the data provided it was not possible to assess the dissociation of DMM into magnesium and
malic acid. The Panel further concluded that if DMM dissociates, magnesium would be available
following ingestion of DMM and the availability would appear similar to values reported for other
sources of magnesium already permitted. Finally, the Panel noted that the proposed use levels could
result in exposures to magnesium greater than its upper level (UL) (250 mg/day) for food supplements
and for food for special medical purposes.
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Summary
The present scientiﬁc opinion deals with the evaluation of the safety of di-magnesium malate
(DMM) proposed as a novel food ingredient and as a source of magnesium for use in foods for the
general population, food supplements, total diet replacement for weight control and food for special
medical purposes (FSMP), and with the bioavailability of magnesium from this source. The safety of
magnesium itself, in terms of amounts that may be consumed, and the consideration of magnesium as
a nutrient are outside the remit of this Panel.
Additional information was sought from the applicant during the assessment process. A ﬁnal
request sent by the European Food Safety Authority (EFSA) in June 2017 did not generate a reply.
Consequently, the Panel concluded this assessment on the basis of the available data.
The Panel noted that the structural formula of the proposed complex, as indicated in the dossier, is
based on expert judgement and not supported by any analytical evidence (e.g. X-ray crystallography).
Following a request for additional information, the applicant did not provide any further data in
support to the proposed structural formula of the proposed complex.
The Panel considered that the scientiﬁc evidence submitted by the applicant does not demonstrate
the difference between ‘dimagnesium malate (DMM)’, which is subject of the application under
evaluation and ‘magnesium malate’ which is already included in Annex II to Directive 2002/46/EC as
one of the mineral substances which may be added to food supplements, following a scientiﬁc opinion
by EFSA AFC Panel (2006).
The applicant provided results from eight lots of DMM that were analysed by high-performance
liquid chromatography (HPLC) for maleic and fumaric acids. No maleic acid was detected in DMM. The
mean concentration of the fumaric acid present in the samples was 0.29%, with a maximum of 0.4%
and a minimum of 0.24%. DMM may contain contamination of lead, arsenic, mercury and cadmium as
a result of inherent contamination in the starting materials. However, the Panel noted that the
certiﬁcates of analysis were not provided by the applicant.
The applicant provided analytical data on particle size of ﬁve non-consecutive lots of DMM.
However, the Panel considered that the described vibratory sieve testing method with the smallest
sieve opening of 45 lm is not appropriate to determine nano-size particles. The Panel also noted that
an average of 10.03% of the tested material passed through the smallest 45 lm sieve.
The Panel noted that the applicant did not submit any information on proposed uses and use levels
for DMM, in the application dossier. Further to a request for additional information, the applicant has
submitted data on the proposed use and use levels of DMM as source of supplemental magnesium in
foods. However, the Panel noted that the values provided by the applicant were expressed in mg/day
instead of mg/kg of food as requested by the EFSA ‘Guidance for submission for food additive
evaluations’ (EFSA ANS Panel, 2012). Further to a request for additional information, the applicant has
submitted data on the proposed use and use levels of DMM as source of supplemental magnesium in
foods. The Panel noted that the food classiﬁcation system used was level 3 of the FoodEx classiﬁcation
system and as such the Panel was unable to complete an exposure estimate for the proposed use of
DMM in foods. The Panel considered converting the data on the proposed use and use levels of DMM
made on the basis of the level 3 of the FoodEx classiﬁcation system into the food categories as
expressed in the FAIM tools (version 1). However, the Panel considered the uncertainties associated
with this would be too great to provide a reliable estimate. Therefore, the Panel did not use this
approach.
The proposed use levels in food supplements indicated by the applicant are intended to provide
from 75 to 375 mg/day of supplemental magnesium, corresponding to an intended intake of
375–1,875 mg/day of DMM from the use in food supplements. With respect to the use in FSMP and
total diet replacement for weight control, at the proposed use levels for DMM the corresponding intake
of magnesium would be 25 mg/day and 150–375 mg/day, respectively. The Panel noted that at the
proposed use levels of DMM, the existing upper level (UL) of 250 mg/day for supplemental magnesium
may be exceeded.
The Panel further noted that, besides a bioavailability study conducted in human volunteers and an
acute toxicity study performed in rats, no further biological and toxicological data on DMM were submitted
by the applicant as part of the dossier. The applicant provided a justiﬁcation for not complying with the
Tier 1 requirements of the 2012 ANS Panel ‘Guidance for submission for food additive evaluations’ by
stating that, following oral ingestion, DMM readily dissociated into magnesium and malic acid.
The dissociation of DMM into its constituents at low pH was investigated by gel ﬁltration by liquid
chromatography (LC), using an acidic solution (pH 2.3), mimicking the pH conditions in the stomach,
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as a mobile phase. However, the Panel considered based on the data provided, that it is not clear
whether the substance under evaluation dissociate into its components (malic acid and magnesium) at
pH 2.3. Despite a request for additional information, the applicant did not provide any additional data
in support of the non-dissociation of DMM into magnesium and malic acid at other pHs. The
Panel considered that the information provided by the applicant was not sufﬁcient to evaluate the
dissociation of DMM into magnesium and malic acid.
On the basis of the available data, the Panel concluded that there was insufﬁcient scientiﬁc
evidence of a difference between the proposed novel food ingredient named as DMM and magnesium
malate already authorised as a source of magnesium included in Annex II to Directive 2002/46/EC.
Accordingly, the Panel was unable to assess the safety of DMM as a novel food ingredient.
The Panel concluded that based on the data provided it was not possible to assess the dissociation
of DMM into magnesium and malic acid. The Panel further concluded that if DMM dissociates,
magnesium would be available following ingestion of DMM and the availability would appear similar to
values reported for other sources of magnesium already permitted.
The Panel noted that the proposed use levels could result in exposures to magnesium greater than
its UL for food supplements and for FSMP.
DMM (di-magnesium malate) as a source of magnesium
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1. Introduction
The present scientiﬁc opinion deals with the evaluation of the safety of di-magnesium malate
(DMM) proposed as a novel food ingredient and as a source of magnesium for use in foods for the
general population, food supplements, total diet replacement for weight control and food for special
medical purposes (FSMP), and with the bioavailability of magnesium from this source. The safety of
magnesium itself, in terms of amounts that may be consumed, and the consideration of magnesium as
a nutrient are outside the remit of this Panel.
1.1. Background and Terms of Reference as provided by the European
Commission
1.1.1. Background
The European Union legislation lists nutritional substances that may be used for nutritional
purposes in certain categories of foods as sources of certain nutrients.
The relevant Union legislative measures are:
• Regulation (EC) No 258/97 of the European Parliament and the Council concerning novel foods
and novel food ingredients1;
• Directive 2002/46/EC of the European Parliament and of the Council on the approximation of
the laws of the Member States relating to food supplements2;
• Regulation (EC) No 1925/2006 on the addition of vitamins and mineral and of certain other
substances to foods3;
• Regulation (EU) No 609/2013 of the European Parliament and of the Council on food intended
for infants and young children, food for special medical purposes, and total diet replacement
for weight control.4
The dossier relating to di-magnesium malate (DMM) as a source of magnesium has been submitted
to the Food Safety Authority of Ireland (FSAI), the competent authority for novel food in Ireland, for
an initial assessment under Article 6(2) of Regulation (EC) No 258/97 concerning novel foods and
novel food ingredients. The applicant has asked the authorisation for di-magnesium malate in many
food categories, including food supplements as a source of magnesium.
On 9 July 2015, FSAI forwarded to the Commission the initial assessment report, concluding that
an additional assessment by the European Food Safety Authority is required in line with Article 6(3) of
that Regulation.
1.1.2. Terms of reference
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20025, the European Commission
asks the European Food Safety Authority to provide a scientiﬁc opinion:
• By carrying out the additional assessment for di-magnesium malate (DMM) as a novel food
ingredient in the context of Regulation (EC) No 258/97, and
• Following the outcome of the novel food assessment by evaluating the safety of di-magnesium
malate (DMM) when added for nutritional purposes as a source of magnesium to food for the
general population, food supplements, total diet replacement for weight control and food for
special medical purposes, and the bioavailability of magnesium from this source, in the context
of Regulation (EC) No 1925/2006, Directive 2002/46/EC and Regulation (EU) No 609/2013.
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6.
2 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the
Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57.
3 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of vitamins
and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26.
4 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive
92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the European
Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009. OJ L 181, 29.6.2013, p. 35.
5 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
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1.2. Information on existing evaluations and authorisations
The applicant provided information on the regulatory status of magnesium oxide and malic acid.
The Panel considered that information on regulatory status of magnesium oxide is not directly relevant
for the assessment of DMM.
1.2.1. Magnesium
The setting of a tolerable upper level (UL) for magnesium was considered by the European Union
(EU) Scientiﬁc Committee on Food (SCF) in 2001. The SCF concluded that osmotic diarrhoea was the
critical effect for establishing an UL for magnesium and identiﬁed a no-observed-adverse-effect-level
(NOAEL) of 250 mg/day of magnesium and an uncertainty factor of 1 for deriving an UL of 250 mg/day
of magnesium for readily dissociable magnesium salts (e.g. chloride, sulfate, aspartate, lactate) and
compounds, such as magnesium oxide, in nutritional supplements, water, or added to food and
beverages. The UL does not include magnesium normally present in foods and beverages and it only
applies to adults, including pregnant and lactating women, and children from 4 years onwards. No UL
could be set for children aged 1–3 years due to lack of data (SCF, 2001).
In 2015, the EFSA NDA Panel issued a scientiﬁc opinion on dietary reference values for magnesium
(EFSA NDA Panel, 2015). In that opinion, data on dietary intake of magnesium in the general
population were reported.
1.2.2. Magnesium malate
In 2006, the former EFSA Panel on Food Additives, Flavourings, Processing Aids and Materials in
Contact with Food (AFC) issued a scientiﬁc opinion on magnesium malate added for nutritional
purposes to food supplements as a source of magnesium. The AFC based its opinion on the previous
safety evaluations of the individual substances, malic acid and magnesium and concluded that the use
of magnesium malate in food supplements as a source of magnesium was of no safety concern (EFSA
AFC Panel, 2006). Magnesium malate is therefore included in Annex II of Directive 2002/46/EC on
vitamin and mineral substances which may be used in the manufacture of food supplements.
1.2.3. Malic acid and malates
According to the applicant, malic acid is an intermediate in the tricarboxylic acid cycle, also known
as the citric acid or Krebs cycle, which is essential for the oxidative metabolism of carbohydrates and
the production of adenosine triphosphate (ATP). The L-isoform of malic acid occurs naturally in apples
and many other fruits and plants (Burdock, 2001; PDRNS, 2001).
Both the Joint FAO/WHO Expert Committee on Food Additives (JECFA, 1980) and the SCF (1991)
concluded that there was clear evidence that both enantiomers of malic acid are readily metabolised
by laboratory animals and humans and that there was no reason to distinguish between L-malic acid
and DL-malic acid when considering their safe use in food.
Calcium malate and calcium citrate malate are included in Annex II of Directive 2002/46/EC on vitamin
and mineral substances which may be used in the manufacture of food supplements, in Annex II of
Regulation (EC) No 1925/2006 on vitamin formulations and mineral substances which may be added to
foods. Calcium malate and calcium citrate malate are also included in the Union list of substances that
may be added to FSMP and total diet replacement for weight control as referred to in Annex of Regulation
(EU) 609/2013.
Zinc and potassium malate are included in Annex II of Directive 2002/46/EC on vitamin and mineral
substances which may be used in the manufacture of food supplements.
Malic acid, and sodium-, sodium hydrogen-, potassium-, calcium- and calcium hydrogen malate
(E 296, E 350–352) are authorised food additives in the EU according to Annex II and Annex III to
Regulation (EC) No 1333/20086 on food additives. Currently, their re-evaluation as food additives is still
ongoing as foreseen in Regulation (EC) No 257/20107. The acceptable daily intake (ADI) ‘not speciﬁed’
was established by JECFA (1980).
6 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives OJ L
354, 31.12.2008, p. 1–16.
7 http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2011-00598;00635
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2. Data and methodologies
2.1. Data
The present evaluation is based on the data on DMM provided by the applicant in a dossier
submitted in support of its application (Documentation provided to EFSA n. 1), an initial assessment
performed by FSAI (Documentation provided to EFSA n. 2), the comments raised by Member States
during the assessment of DMM as a novel food ingredient (Documentation provided to EFSA n. 3) and
subsequent response by the applicant (Documentation provided to EFSA n. 4).
Additional information was sought from the applicant during the assessment process
(Documentation provided to EFSA n. 6, 7).
However, despite several requests, the applicant did not provide the additional data. A ﬁnal request
sent by EFSA in June 2017 did also not generate a reply. Consequently, the Panel concluded this
assessment on the basis of the available data.
2.2. Methodologies
The assessment was conducted in line with the principles described in the EFSA Guidance on
transparency in the scientiﬁc aspects of risk assessment (EFSA, 2009) and following the relevant
existing Guidances from the EFSA Scientiﬁc Committee.
The ANS Panel assessed the safety of DMM as a novel food ingredient in line with the principles laid
down in Commission Recommendation 97/618/EC.8 In particular, where it is stated that ‘Most of the
deﬁned chemical substances can probably be tested for their safety similarly to food additives by
utilising conventional methods of safety evaluation as described in the SCF Report No 10.’, the
Panel considered that to reﬂect state of the art scientiﬁc knowledge and welfare considerations the
reference to SCF Report No 10 should be replaced by the latest existing guidance on the safety
evaluation of food additives, namely the Guidance for submission for food additive evaluations in 2012
(EFSA ANS Panel, 2012).
With respect to the evaluation of bioavailability of the nutrient (magnesium) from the source DMM,
the principles contained in the ‘Guidance on submissions for safety evaluation of nutrients or of other
ingredients proposed for use in the manufacture of foods’ (SCF, 2001) were followed.
3. Assessment
3.1. Technical data
3.1.1. Identity of the substance
According to the applicant (‘Documentation provided to EFSA’ n. 1), DMM is a compound containing
a magnesium malate complex and is described as follows:
Chemical name: Di-magnesium malate
CAS number: 671197-50-5
Synonyms: DMM; magnesium malate complex; magnesium (II) malate complex;
magnesium malate; dimagnesium malate complex; dimagnesium
dihydroxy malate; tetra magnesium dimalate; hydroxybutanedioic
magnesium; dimagnesium hydroxybutanedioate; tetramagnesium
dihydroxybutanedioate
Trade name Dimagnesium malate (DMM)
Chemical formula Mg2(OH)2C4H4O5
Molecular weight 171.44 g/mol
Description of physical state Free-ﬂowing and hygroscopic white powder
8 Commission Recommendation No 97/618 (EC) concerning the scientiﬁc aspects and the presentation of information necessary
to support applications for the placing on the market of novel foods and novel food ingredients and the preparation of initial
assessment reports under Regulation (EC) No 258/97 of the European Parliament and of the Council (Text with EEA relevance)
OJ L 253, 16.9.1997, p. 1–36.
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Solubility Soluble to freely soluble in water and very slightly soluble in ethanol
and acetone in accordance with the solubility deﬁnition given by United
States Pharmacopeia (USP)9
The Panel noted that the molecular weight of DMM as provided by the applicant in the dossier
(171.44 g/mol) does not match the molecular weight calculated on the basis of the chemical formula
provided (214.60 g/mol).
The structural formula of DMM complex as proposed by the applicant is given in Figure 1. The
Panel noted that the structural formula of the proposed complex, as indicated in the dossier, is based
on expert judgement and not supported by any analytical evidence (e.g. X-ray crystallography).
Further to a request for additional information, the applicant did not provide any additional data in
support to the proposed structural formula of the proposed complex.
The Panel noted that according to the information available in the SciFinder database, the formula
associated with the CAS number provided by the applicant (CAS 671197-50-5) is not speciﬁc and the
CAS number cannot be unambiguously associated with the material, which is the subject of this
application. Further to a request for additional information, the applicant did not provide any additional
data on the availability of a CAS number for the proposed complex.
The identity of the product was determined through the analysis of total composition as well as
with Fourier-transforming infrared (FTIR) and mass spectroscopies. The Panel noted that the mass
spectrum was not provided in the application dossier. Based on the analysis of infrared and mass
spectra, the applicant concluded that DMM was a unique magnesium malate compound rather than a
mixture of magnesium and malic acid.
The shifts in the FTIR spectrum of DMM shows coordination between carboxylate and the metal
but that do not permit to reach any conclusion on the structure of DMM. The applicant compared the
FTIR spectrum of DMM with the one from disodium malate and proposed a molecule with the
structure presented in Figure 2. The Panel noted that this structure is different from the one proposed
in the same application dossier and presented in Figure 1.
9 Solubility definition given by USP. Parts of solvent required for 1 part of solute: less than 1 (very soluble); from 1 to 10 (freely
soluble); from 10 to 30 (soluble); from 30 to 100 (sparingly soluble); from 100 to 1,000 (slightly soluble); from 1,000 to 10,000
(very slightly soluble); greater than or equal to 10,000 (practically insoluble).
Figure 1: Structural formula of the di-magnesium malate (DMM) complex, as proposed by the
applicant (‘Documentation provided to EFSA’ n. 1)
(HO)MgO
OMg(OH)
O OH
O
Figure 2: Structural formula for DMM as proposed by the applicant in the report on ‘dimagnesium
malate molecular structure data’ Appendix B (‘Documentation provided to EFSA’ n. 1)
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However, the Panel considered that these results alone would not be sufﬁcient to characterise the
proposed DMM as a complex and that additional analytical evidence (e.g. X-ray crystallography) has
been requested but never provided by the applicant.
Results on the composition of eight lots of DMM were provided by the applicant indicating the
concentration of each component (magnesium and malic acid). The results are reported in Table 1.
The content of magnesium and malate was analysed using inductively coupled plasma (ICP)
spectrometry and high-performance liquid chromatography (HPLC), respectively. Moisture was
calculated theoretically on the basis of the percentage of magnesium and malate.
According to the applicant the purity of DMM can be determined through the analysis of
magnesium content using inductively coupled plasmaatomic emission spectrometry (ICP-AES).
According to the applicant, the two geometric isomers fumaric and maleic acid are possible impurities
that could occur in malic acid based on the proposed manufacturing process.
Industrially, racemic malic acid is produced by the hydration of the double bond of maleic acid. It is
possible that there could be residual maleic or fumaric acids in the malic acid raw material. Neither
fumaric nor maleic acids would be formed during the manufacturing of DMM.
The applicant provided results from eight lots of DMM that were analysed by HPLC for maleic and
fumaric acids. No maleic acid was detected in DMM. The mean concentration of the fumaric acid
present in the samples was 0.29%, with a maximum of 0.40% and a minimum of 0.24%.
According to the applicant, DMM may contain contamination of lead, arsenic, mercury and cadmium
as a result of inherent contamination in the starting materials. However, the Panel noted that the
certiﬁcates of analysis of these toxic elements in DMM were not provided by the applicant.
The Panel noted that, according to the applicant, the DMM is soluble to freely soluble in water.
Upon request from EFSA, the applicant provided analytical data on particle size of ﬁve non-
consecutive lots of DMM (Documentation provided to EFSA n. 6) tested using a vibratory sieve testing
apparatus. Each lot was analysed without replication. The Panel noted that the applicant provided a
description of the method of analysis used. Information on the percentage of the total mass retained
above or on top of each sieve, on the cumulative percentage of the total mass retained above or on
top of each sieve as a progression through the sieve nest and on the percentage of the total mass
that passed through each sieve was provided. The data are summarised in Table 2.
Table 1: Concentration of magnesium and malic acid based on results on eight lots of DMM
Constituent Average (%) Maximum (%) Minimum (%)
Magnesium 22.05 22.53 21.46
Malic acid 54.35 56.40 53.10
Moisture 9.83 11.14 8.26
DMM: di-magnesium malate.
Table 2: Results of particle size distribution analysis of 5 batches of di-magnesium malate (DMM)
US sieve number
Opening
(lm)
Percentage
above (%)
Cumulative
above (%)
Percentage
below (%)
Ave SD RSD Ave SD RSD Ave SD RSD
35 500 0.02 0.03 171 0.02 0.03 171 99.98 0.03 0
45 355 0.27 0.14 53 0.29 0.12 43 99.71 0.12 0
60 250 0.64 0.19 30 0.92 0.28 30 99.08 0.28 0
80 180 1.45 0.32 22 2.37 0.54 23 97.63 0.54 1
120 125 2.70 0.83 31 5.08 1.06 21 94.92 1.06 1
170 90 17.25 6.04 35 22.33 5.90 26 77.67 5.90 8
230 63 40.46 4.94 12 62.79 8.00 13 37.21 8.00 21
325 45 27.18 7.95 29 89.97 3.85 4 10.03 3.85 38
Pan N/A 10.03 3.85 38 100.00 0.00 0 0.00 0.00 N/A
Ave: average; SD: standard deviation; RSD: residual standard deviation; N/A: not applicable.
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On the basis of the data provided by the applicant, the Panel considered that the described
vibratory sieve testing method with the smallest sieve opening of 45 lm is not appropriate to
determine nano-size particles. The Panel also noted that an average of 10% of the tested material
passed through the smallest 45 lm sieve.
The Panel noted that there is an inconsistency in the documentation provided by the applicant with
regards to the structure of the substance under evaluation: the structural formula presented in the
application dossier refers to a complex (Figure 1) and it is different from the structural formula
presented in one of the appendixes of the application dossier (Figure 2) (‘Documentation provided to
EFSA’ n. 1). Additionally, the Panel considered that the scientiﬁc evidence submitted by the applicant
(initial application dossier and additional data provided) does not demonstrate the difference between
‘dimagnesium malate (DMM)’, which is subject of the application under evaluation and ‘magnesium
malate’ which is already included in the Annex II to Directive 2002/46/EC as one of the mineral
substances which may be added to food supplements, following a scientiﬁc opinion by EFSA AFC
Panel (2006).
3.1.2. Speciﬁcations
The speciﬁcations for DMM as proposed by the applicant are listed in Table 3.
The Panel noted that the description in the proposed speciﬁcations (white to white off powder) was
more limited than that given in the identity of the substance (free ﬂowing and hygroscopic white
powder). The Panel noted that no ﬂowability data were provided by the applicant.
Furthermore, the Panel noted that the currently proposed speciﬁcations indicate a minimum limit
for magnesium and malic acid whilst no maximum limits are provided.
The Panel also noted that the currently proposed speciﬁcations indicate a range of solubility in
water for the complex (from soluble to freely soluble). The Panel noted that the results of the solubility
test in support of the proposed classiﬁcation range were not provided in the application dossier
(‘Documentation provided to EFSA’ n. 1).
Table 3: Speciﬁcation for DMM as proposed by the applicant
Speciﬁcation parameter Speciﬁcation value Method of analysis
Technical characteristics
Description White to off-white powder Visual inspection
Identiﬁcation Passes test FTIR analysis
Assay
Magnesium content Not less than 20% ICP-AES
Malic acid content Not less than 52% HPLC
pH value 10–11 pH meter
Moisture/Loss on drying Not more than 12% Moisture balance
Fumaric acid content Not more than 1.0% HPLC
Maleic acid Not more than 0.05% HPLC
Heavy metals
Arsenic Not more than 3.0 ppm ICP-MS
Lead Not more than 1.5 ppm ICP-MS
Cadmium Not more than 0.5 ppm ICP-MS
Mercury Not more than 0.1 ppm ICP-MS
Microbiological speciﬁcations
Total plate count Not more than 1,000 FDA BAM 8th edition
Yeast and moulds Not more than 100 AOAC 995.21
Coliform count Negative FDA BAM 8th edition
Escherichia coli Negative FDA BAM 8th edition
Staphylococcus aureus Negative FDA BAM 8th edition
Salmonella Negative AOAC 991.12
FTIR: Fourier-transforming infrared; HPLC: high-performance liquid chromatography; ICP-MS: inductively coupled plasma mass
spectrometry; BAM: bacteriological analytical manual; nd: not detectable information available.
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Further to a request for additional information, the applicant did not provide any additional data in
support to the currently proposed speciﬁcations of DMM.
According to the applicant, the impurities resulting from the manufacturing process include arsenic
(≤ 0.003%), lead (≤ 0.0015%), cadmium (≤ 0.0005%) and mercury (≤ 0.0001%) that correspond to
≤ 30 ppm (arsenic), ≤ 15 ppm (lead), ≤ 5 ppm (cadmium) and ≤ 1 ppm (mercury). Speciﬁcations for
DMM include parameters for all impurities, and each batch manufactured is tested to ensure that the
purity criteria are met. However, the Panel noted that analytical data provided by the applicant are not
in agreement with those reported in the speciﬁcations.
The Panel noted that the applicant submitted results on eight non-consecutive batch analyses on
DMM. However, the certiﬁcates of analysis were provided for a single batch that was not included in
the analysis. Consequently, on the basis of the information provided the Panel was unable to evaluate
whether DMM is produced in compliance with the proposed speciﬁcations (‘Documentation provided to
EFSA’ n. 1).
3.1.3. Manufacturing process
The Panel noted that the information on the manufacturing process as provided by the applicant in
the application dossier (‘Documentation provided to EFSA’ n. 1) was claimed to be conﬁdential.
According to information provided by the applicant, DMM is manufactured from magnesium oxide
powder (purity: 96.0–100.5%) and DL-malic acid (purity: 99–100.5%) as starting materials, under
aqueous conditions.
In the process, DL-malic acid and magnesium oxide are dissolved in water and mixed under
controlled temperature. The resulting solution is then spray-dried and packed.
It is stated that the DL-malic acid used as raw material meets USP grade speciﬁcations and is
equivalent to food-grade material; the magnesium oxide powder also meets Food Chemicals Codex
speciﬁcations (FCC, 2003a,b).
The applicant provided information indicating that DMM is manufactured under good manufacturing
practices (GMP) and in accordance with the Hazard Analysis Critical Control Point system (HACCP).
The Panel considered that the method outlined by the applicant sufﬁciently described the
manufacturing process for a magnesium malate; however, it does not demonstrate the speciﬁc
production of DMM.
3.1.4. Methods of analysis in food
According to the applicant, the level of magnesium as DMM added to foodstuff may be determined
by the inductively coupled plasma/atomic emission spectroscopy (ICP-AES) method. According to the
applicant each milligram of magnesium assayed is equivalent to 5 mg of DMM.
The Panel noted that the applicant did not provide any information on direct method for analysis of
DMM in foodstuff. Further to a request for additional information, the applicant did not submit any
additional data in support of the availability of direct method for analysis of DMM in food.
3.1.5. Stability of the substance, and reaction and fate in food
The mineral content (magnesium) and pH stability of ﬁve non-consecutive batches of DMM has
been evaluated by the applicant over a period of 3 years. According to the applicant, the products
were tested at the time of release for all speciﬁcations in effect at the time of release. The samples
were stored in a polystyrene container with a screw-top lid at ambient temperature and humidity in a
controlled access room. At the end of 3 years, the samples were tested again for all speciﬁcations that
were initially tested (Documentation provided to EFSA n. 1).
The Panel noted that the stability data submitted from a 3-year test provided indication only on the
variations in the total amount of Mg and pH during that period (Documentation provided to EFSA n. 1).
However, the Panel noted that the data submitted did not provide indications on the stability of the
proposed complex of DMM during storage time. Furthermore, the Panel noted that no information on
effect of temperature on the stability of DMM in the food matrix was provided by the applicant.
According to the applicant, in the event of degradation of DMM, the expected degradation products
would be magnesium ions, hydroxide ions (OH) and malic acid., It is not expected that magnesium
ions or malic acid would cause lipid peroxidation or other organoleptic change (Documentation
provided to EFSA n. 1).
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Further to a request for additional information, the applicant did not provide any additional data in
support to the stability of DMM.
On the basis of the data available, the Panel was unable to conclude on the stability of the complex
DMM (Documentation provided to EFSA n. 1).
3.2. Proposed uses and use levels
3.2.1. Use in foods for the general population according to Regulation (EC)
No 1925/2006
The Panel noted that the applicant did not submit any information on proposed uses and use levels
for DMM, in the application dossier (‘Documentation provided to EFSA’ n. 1).
Further to a request for additional information, the applicant has submitted data on the proposed
use and use levels of DMM as a source of supplemental magnesium in foods. However the Panel noted
that the values provided by the applicant were expressed in mg/day instead of mg/kg of food as
requested by the EFSA ‘Guidance for submission for food additive evaluations’ (EFSA ANS Panel,
2012). The Panel noted that the typical and the maximum use levels, as provided by the applicant,
were 300 and 1,875 mg DMM/kg of food, respectively, for all the food categories proposed,
corresponding to 60 and 375 mg magnesium/kg of food for the typical and the maximum levels
(‘Documentation provided to EFSA’ n. 6).
Moreover, the Panel noted that, the food classiﬁcation system used the level 3 of the FoodEx
classiﬁcation system and as such the Panel was unable to complete an exposure estimate for the
proposed use of DMM in foods (Documentation provided to EFSA n. 7). The additional information
submitted is presented in Annex A.
3.2.2. Use in food supplements according to Directive 2002/46/EC
In addition to use in food, the applicant requested the inclusion of DMM as a source of magnesium
in food supplements among the authorised substances included in Annex II of Directive 2002/46/EC.
According to the data provided by the applicant, the use of DMM in food supplements would
provide from 375 to 1,875 mg/day of DMM. This would correspond to 75–375 mg/day of magnesium
(Documentation provided to EFSA n. 6).
3.2.3. Use in food for special medical purposes and total diet replacement for
weight control according to Regulation (EU) No 609/2013
The applicant is also proposing the use of DMM in FSMP at levels providing 25 mg/day of
magnesium corresponding to 125 mg/day of DMM in individuals consuming FSMP.
According to the data provided by applicant, the use of DMM in food for total diet replacement for
weight control would provide from 750 to 1,875 mg/day of DMM. This would correspond to
150–375 mg/day of magnesium.
3.3. Exposure data
The Panel noted that the applicant did not provide any overall estimate for the daily intake of DMM
and the corresponding intake of magnesium, resulting from each proposed use of DMM in foods.
The Panel considered converting the data on the proposed use and use levels of DMM made on the
basis of the level 3 of the FoodEx classiﬁcation system into the food categories as expressed in the
FAIM tools (version 1). However, the Panel considered the uncertainties associated with this would be
too great to provide a reliable estimate. Therefore, the Panel did not use this approach.
The proposed used levels in food supplements indicated by the applicant are intended to provide
from 75 to 375 mg/day of supplemental magnesium, corresponding to an intended intake of
375–1,875 mg/day of DMM.
With respect to the use in FSMP and total diet replacement for weight control, at the proposed use
levels for DMM the corresponding intake of magnesium would be 25 mg and 150–375 mg/day,
respectively.
The Panel noted that at the proposed use levels of DMM, the existing UL of 250 mg/day for
supplemental magnesium may be exceeded.
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3.4. Biological and toxicological data
The Panel noted that, besides a bioavailability study conducted in human volunteers and an acute
toxicity study performed in rats, no further biological and toxicological data on DMM were submitted
by the applicant as part of the dossier.
The applicant provided a justiﬁcation for not complying with the Tier 1 requirements in the
‘Guidance for submission for food additive evaluations’ (EFSA ANS Panel, 2012) by stating that,
following oral ingestion, DMM readily dissociated into magnesium and malic acid.
3.4.1. Bioavailability of magnesium from DMM
Data on dissociation of DMM
The Panel noted that the applicant has provided results from an experimental study in support of the
dissociation of DMM at low pH into magnesium and malic acid (Documentation provided to EFSA n. 1).
The dissociation of DMM into its constituents at low pH was investigated by gel ﬁltration by liquid
chromatography (LC), using an acidic solution (pH 2.3), mimicking the pH conditions in the stomach,
as a mobile phase. The study was designed to provide some evidence to support that DMM, when
placed into acidic solution like that found in the stomach, dissociated into its individual components
(magnesium and malic acid).
Different fractions were collected, evaporated and re-dissolved. The detection of the eluted organic
acids (malic, maleic and fumaric) in each fraction was made by HPLC (UV–vis spectrometer) and
magnesium concentrations were determined by titration with EDTA, using Eriochrome black as
indicator (Documentation provided to EFSA n. 1).
If the DMM complex was intact, the methodology used (separation based on molecular weight)
would result in this being eluted before the organic acids. The liquid chromatogram obtained showed
two major peaks (corresponding to the collected fractions 3 and 5, respectively). The analysis of the
fractions conﬁrmed that malic acid was the main component in the fraction 3, but this fraction did not
contain the magnesium amount that would be expected in a DMM complex, and that fumaric acid was
the main component in the fraction 5 but likewise the corresponding fraction showed no magnesium
that would indicate complexation. Magnesium was present at the highest concentration in the ﬁnal
fraction (fraction 6) and no other compounds were found in signiﬁcant amount in this fraction,
indicating that magnesium was not complexed to any other constituents in the solution. Additionally,
the Panel noted the presence of maleic acid in fractions 2, 4 and 6, even though the applicant has
stated that maleic acid is not present in DMM (Section 3.1.1).
However, the Panel considered based on the description of the method as above, that it is not clear
whether the substance under evaluation dissociate into its components (malic acid and magnesium) at
pH 2.3.
Despite a request for additional information, the applicant did not provide any additional data in
support of the non-dissociation of DMM into magnesium and malic acid at other pHs.
On the basis of the data available, the Panel concluded that the information provided by the
applicant is not sufﬁcient to evaluate the dissociation of DMM into magnesium and malic acid;
consequently, Tier 1 toxicity studies would be needed to evaluate the safety of DMM.
Human data
The bioavailability and tolerability of magnesium from four magnesium supplements (magnesium
oxide, magnesium bisglycinate chelate, magnesium bisglycinate chelate buffered and DMM) was
investigated in an unpublished randomised, double-blind, four-arm cross-over study in 14 healthy
volunteers, performed in accordance with Good Clinical Practice (GCP) in 2007 (Documentation
provided to EFSA n. 1). Each participant received 150 mg as bolus dose of one of the four magnesium
supplements per visit, with a minimum of a 2- week wash out period between visits for a total of four
visits. Bioavailability was determined by serum magnesium levels and tolerability was determined by
adverse event reporting.
None of the subjects was discontinued from the study due to adverse events.
Serum samples were taken at 0, 1, 2, 3, 4, 8, 12 and 24 h post-treatment. The areas under the
curve (AUC) of magnesium for magnesium bisglycinate, magnesium bisglycinate buffered, DMM and
magnesium oxide were 0.164, 0.225, 0.196 and 0.109, respectively. The results were statistically lower
for magnesium oxide in comparison to the other magnesium forms. According to the authors,
magnesium from magnesium bisglycinate, magnesium bisglycinate buffered and DMM showed a higher
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bioavailability compare to that from magnesium oxide. According to the applicant, systemic availability
of magnesium from DMM was comparable to that of other sources already permitted.
3.4.2. Acute toxicity
DMM from a single lot has been evaluated in an unpublished single-dose oral toxicity study
conducted in accordance with Good Laboratory Practice (GLP) in three healthy female Wistar albino rats
(Documentation provided to EFSA n. 1). No mortality was recorded at 5,000 mg/kg body weight (bw).
3.5. Discussion
The current assessment by the Panel is based on the information submitted in the application
dossier (Documentation provided to EFSA n. 1) and the additional information provided by the
applicant in response to EFSA’s requests (Documentation provided to EFSA n. 6, 7). However, despite
several requests, the applicant did not provide the additional data. A ﬁnal request sent by EFSA in
June 2017 also did not generate a reply. Consequently, the Panel concluded this assessment on the
basis of the available data.
According to the applicant, DMM is a compound containing a magnesium malate complex.
However, the Panel considered that the identity of DMM as a complex has not been demonstrated.
The Panel noted that the manufacturing process described for DMM does not demonstrate that the
synthesis of DMM is different from that of magnesium malate.
In the absence of scientiﬁc evidence, the Panel considered that it is not possible to distinguish
between the proposed substance and a salt of magnesium and malic acid. The Panel has requested
scientiﬁc data to demonstrate that the substance under evaluation is different from ‘magnesium
malate’, which is already included in the Annex II to Directive 2002/46/EC, and the applicant was not
able to provide any scientiﬁc evidence. In the absence of these data, the Panel is unable to conclude
that the substance presented as DMM would be different from magnesium malate already authorised
as a nutrient source.
The applicant has proposed chemical and microbiological speciﬁcations for DMM and provided
results from eight non-consecutive batches. However, the certiﬁcates of analysis were provided for a
single batch that was not included in the analysis. Consequently, on the basis of the information
provided the Panel was unable to evaluate whether DMM is produced in compliance with the proposed
speciﬁcations.
According to the applicant, DMM is expected to remain stable for up to 3 years under normal
storage condition. However, the Panel noted that the results on stability tests as provided by the
applicant refer to the magnesium content and not to DMM as a complex. Moreover, the Panel noted
that no information on the effect of temperature on the stability of DMM in a food matrix was provided
by the applicant. On the basis of the data available, the Panel was unable to conclude on the stability
of the complex DMM.
The Panel considered that the data provided by the applicant on the proposed uses and use levels
were not adequate to allow the reliable calculation of the exposure to DMM.
On the basis of the information provided by the applicant, the Panel noted that the intake of
magnesium from food fortiﬁed with DMM in addition to the proposed use in food supplements, FSMP
and food for total diet replacement for weight control, would lead to an exceedance of the UL for
supplemental magnesium (250 mg/day).
The Panel further noted that the toxicological data set was limited to an acute oral toxicity study
and a randomised, double-blind, four-arm crossover study performed in healthy human volunteers with
limited safety parameters.
According to the applicant, DMM at low pH dissociates into its main components (magnesium and
malic acid). Despite a request for additional information, the applicant did not provide any additional
data in support of the non-dissociation of DMM into magnesium and malic acid at other pHs.
On the basis of the data available, the Panel concluded that the information provided by the
applicant is not sufﬁcient to evaluate the dissociation of DMM into magnesium and malic acid;
consequently, Tier 1 toxicity studies would be needed to evaluate the safety of DMM.
On the basis of the data submitted by the applicant, the Panel considered that magnesium is
bioavailable from the source.
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4. Conclusions
On the basis of the available data, the Panel concluded that there was insufﬁcient scientiﬁc
evidence of a difference between the proposed novel food ingredient named as DMM and magnesium
malate already authorised as a source of magnesium included in Annex II to Directive 2002/46/EC.
Accordingly, the Panel was unable to assess the safety of DMM as a novel food ingredient.
The Panel concluded that based on the data provided it was not possible to assess the dissociation
of DMM into magnesium and malic acid. The Panel concluded that if DMM dissociates, magnesium
would be available following ingestion of DMM and the availability would appear similar to values
reported for other sources of magnesium already permitted.
The Panel noted that the proposed use levels could result in exposures to magnesium greater than
its UL for food supplements and for FSMP.
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Abbreviations
ADI acceptable daily intake
ANS Panel EFSA Panel on Food additives and Nutrient Sources added to Food
ATP adenosine triphosphate
AUC area under the curve
BAM bacteriological analytical manual
bw body weight
CAS Chemical Abstracts Service
DMM di-magnesium malate
FAIM Food additives Intake Model
FCC Food Chemical Codex
FSMP Food for special medical purposes
FTIR Fourier-transforming infrared
GI gastrointestinal
GCP Good Clinical Practice
GLP Good Laboratory Practice
GMP Good Manufacturing Practices
HACCP Hazard Analysis Critical Control Point system
HPLC high-performance liquid chromatography
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JECFA Joint FAO/WHO Expert Committee on Food Additives
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USP United States Pharmacopeia
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Annex A – Proposed use and use levels as provided by the applicant (Documentation provided to EFSA n. 7)
Code IntendedTree Corex
Amount
DMM/kg
food
Maximum
DMM/kg
food
A000J Grain and grain-based products H
A000K Cereals and cereal primary derivatives H
A000L Cereal grains (and cereal-like grains) M
A001X Mixtures of grains C 320 mg 1,925 mg
A0D9Y Barley and similar C 320 mg 1,925 mg
A04KH Buckwheat and other pseudo-cereals and similar C 320 mg 1,925 mg
A000S Maize and similar C 320 mg 1,925 mg
A000Y Common millet and similar C 320 mg 1,925 mg
A000F Oat and similar C 320 mg 1,925 mg
A001C Rice and similar C 320 mg 1,925 mg
A0D9R Rye and similar C 320 mg 1,925 mg
A0D9Q Sorghum and similar C 320 mg 1,925 mg
A04KR Cereals and cereal-like grains not separately listed H
A001M Wheat and similar C 320 mg 1,925 mg
A04KS Cereal and cereal-like ﬂours M
A004S Flour mix (like wheat/rye/barley/oats and other) C 320 mg 1,925 mg
A002E Amaranth ﬂour C 320 mg 1,925 mg
A002L Barley ﬂour C 320 mg 1,925 mg
A002G Buckwheat ﬂour C 320 mg 1,925 mg
A0C0Z Maize, milled C 320 mg 1,925 mg
A002T Millet ﬂour C 320 mg 1,925 mg
A002Y Oat ﬂour C 320 mg 1,925 mg
A003F Rice ﬂour C 320 mg 1,925 mg
A003J Rye ﬂour C 320 mg 1,925 mg
A003T Sorghum ﬂour C 320 mg 1,925 mg
A004H Spelt ﬂour C 320 mg 1,925 mg
A003X Wheat ﬂour C 320 mg 1,925 mg
A0BY1 Groats M
A065N Barley groats C 320 mg 1,925 mg
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Code IntendedTree Corex
Amount
DMM/kg
food
Maximum
DMM/kg
food
A002H Buckwheat groats C 320 mg 1,925 mg
A002V Millet groats C 320 mg 1,925 mg
A002Z Oat groats C 320 mg 1,925 mg
A003P Rye groats C 320 mg 1,925 mg
A004E Wheat groat C 320 mg 1,925 mg
A004G Bulgur C 320 mg 1,925 mg
A0ETL Semolina M
A002N Maize semolina C 320 mg 1,925 mg
A004F Wheat semolina C 320 mg 1,925 mg
A0F6Q Rice semolina C 320 mg 1,925 mg
A002C Cereal bran M 320 mg 1,925 mg
A003B Oat bran C 320 mg 1,925 mg
A003Q Rye bran C 320 mg 1,925 mg
A004P Wheat bran C 320 mg 1,925 mg
A0F6P Rice bran C 320 mg 1,925 mg
A00CV Breakfast cereals H
A04LH Breakfast cereals, plain H
A04LJ Cereal rolled grains M
A00EH Mixed cereal rolled grains C 320 mg 1,925 mg
A00CY Barley rolled grains C 320 mg 1,925 mg
A00DF Millet rolled grains C 320 mg 1,925 mg
A00DH Oat rolled grains C 320 mg 1,925 mg
A00DQ Rice rolled grains C 320 mg 1,925 mg
A00DV Rye rolled grains C 320 mg 1,925 mg
A00EA Spelt rolled grains C 320 mg 1,925 mg
A00EB Wheat rolled grains C 320 mg 1,925 mg
A00EC Wheat germs rolled ﬂakes C 320 mg 1,925 mg
A00ED Wheat bran rolled ﬂakes C 320 mg 1,925 mg
A00EN Porridge (in dry form, to be diluted) M
A00EX Barley porridge C 320 mg 1,925 mg
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Code IntendedTree Corex
Amount
DMM/kg
food
Maximum
DMM/kg
food
A00ET Cornmeal porridge C 320 mg 1,925 mg
A00EQ Oat porridge C 320 mg 1,925 mg
A00ER Rice porridge C 320 mg 1,925 mg
A00ES Rye porridge C 320 mg 1,925 mg
A00EV Wheat semolina porridge C 320 mg 1,925 mg
A00EY Cereal bars C 320 mg 1,925 mg
A010R Sugar plants H
A0ETE Roots used as sugar source M
A0CXQ Sugar beet roots and similar C 320 mg 1,925 mg
A0CXM Chicory roots and similar C 320 mg 1,925 mg
A0ESQ Stalks/canes/trunk sap or similar for sugar M
A0CXP Sugar canes and similar C 320 mg 1,925 mg
A04HB Other sugar plants C 320 mg 1,925 mg
A02LR Milk and dairy products H
A04NN Milk, whey and cream H
A02LT Milk M
A02LV Cow milk C 192 mg/L 1,925 mg/L
A02MB Goat milk C 192 mg/L 1,925 mg/L
A02MP Flavoured milks C 192 mg/L 1,925 mg/L
A02MZ Fermented milk or cream H
A02NQ Yoghurt drinks, sweetened and/or ﬂavoured C 192 mg/L 1,925 mg/L
A02PD Milk and dairy powders and concentrates M
A04NR Other dairy concentrate H
A02PJ Milk powder C 192 mg/L 1,925 mg/L
A02PM Cream powder C 192 mg/L 1,925 mg/L
A02PN Whey powder C 192 mg/L 1,925 mg/L
A032F Sugar and similar, confectionery and water-based sweet desserts H
A04PA Sugar and other sweetening ingredients (excluding intensive sweeteners) H
A032G Sugars (mono- and di-saccharides) H
A032H Sucrose (common sugar) C 320 mg 1,925 mg
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Code IntendedTree Corex
Amount
DMM/kg
food
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DMM/kg
food
A033R Syrup (molasses and other syrups) M
A033S Molasses C 320 mg 1,925 mg
A033Z Syrups C 320 mg 1,925 mg
A033J Honey C 320 mg 1,925 mg
A04PB Other sweetening ingredients H
A032Z Polyols C 320 mg 1,925 mg
A0F7R Table-top sweeteners formulations M
A0F7T Table-top sweeteners in liquid form C 320 mg 1,925 mg
A0F7V Table-top sweeteners in powder form C 320 mg 1,925 mg
A0F7X Table-top sweeteners in tables C 320 mg 1,925 mg
A039K Fruits and vegetable juices and nectars (including concentrates) H
A0BX9 Fruits/vegetable juices and nectars M
A03AN Mixed fruit juice C 192 mg/L 1,925 mg
A039M Juice, apple C 192 mg/L 1,925 mg
A03AM Juice, orange C 192 mg/L 1,925 mg
A039T Juice, cranberry C 192 mg/L 1,925 mg
A039N Juice, apricot C 192 mg/L 1,925 mg
A03AL Juice, grapefruit C 192 mg/L 1,925 mg
A03AF Juice, pineapple C 192 mg/L 1,925 mg
A04PN Other fruit juices H
A039P Juice, black currant C 192 mg/L 1,925 mg
A039S Juice, blackberry C 192 mg/L 1,925 mg
A03AG Juice, citrus C 192 mg/L 1,925 mg
A039V Juice, elderberry C 192 mg/L 1,925 mg
A03AK Juice, grape C 192 mg/L 1,925 mg
A039X Juice, guava C 192 mg/L 1,925 mg
A03AH Juice, lemon C 192 mg/L 1,925 mg
A03AJ Juice, lime C 192 mg/L 1,925 mg
A039Y Juice, mango C 192 mg/L 1,925 mg
A039Z Juice, nectarine C 192 mg/L 1,925 mg
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A03AA Juice, passion fruit C 192 mg/L 1,925 mg
A03AB Juice, peach C 192 mg/L 1,925 mg
A03AC Juice, pear C 192 mg/L 1,925 mg
A03AD Juice, pomegranate C 192 mg/L 1,925 mg
A03AE Juice, prune C 192 mg/L 1,925 mg
A039R Juice, red currant C 192 mg/L 1,925 mg
A04PS Other (mixed) fruit and vegetable juices or nectars H
A03DC Juice, apple–carrot C 192 mg/L 1,925 mg
A03DD Juice, multifruit–carrot C 192 mg/L 1,925 mg
A04PT Other mixed fruit and vegetable juices H
A03DF Fruit smoothies C 192 mg/L 1,925 mg
A03DH Multivitamin juices C 192 mg/L 1,925 mg
A03BM Concentrated or dehydrated fruit/vegetables juices H
A0ETV Fruit/vegetable juice concentrate M
A03BP Juice concentrate, apricot C 192 mg/L 1,925 mg
A03BQ Juice concentrate, blackberry C 192 mg/L 1,925 mg
A03BR Juice concentrate, blueberry C 192 mg/L 1,925 mg
A03BS Juice concentrate, black currant C 192 mg/L 1,925 mg
A03BT Juice concentrate, red currant C 192 mg/L 1,925 mg
A03BV Juice concentrate, cranberry C 192 mg/L 1,925 mg
A03BX Juice concentrate, gooseberry C 192 mg/L 1,925 mg
A03BY Juice concentrate, grape C 192 mg/L 1,925 mg
A03BZ Juice concentrate, mandarin C 192 mg/L 1,925 mg
A03CA Juice concentrate, orange C 192 mg/L 1,925 mg
A03CB Juice concentrate, peach C 192 mg/L 1,925 mg
A03CC Juice concentrate, plum C 192 mg/L 1,925 mg
A03CD Juice concentrate, raspberry C 192 mg/L 1,925 mg
A03CE Juice concentrate, strawberry C 192 mg/L 1,925 mg
A03CF Juice concentrate, sweet cherry C 192 mg/L 1,925 mg
A03CZ Vegetable juice concentrate C 192 mg/L 1,925 mg
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A03DJ Water and water-based beverages H
A03DK Drinking water M
A03DQ Natural mineral water C 19 mg/L 384 mg/L
A03DT Bottled drinking water C 19 mg/L 384 mg/L
A03DY Flavoured bottled water C 19 mg/L 384 mg/L
A03GC Fortiﬁed bottled water C 19 mg/L 384 mg/L
A04PY Water based beverages H
A03FZ Functional drinks M
A03GB Isotonic and sport drinks C 192 mg/L 1,925 mg/L
A04PZ Beverages concentrates H
A03GD Drink mixes M
A03GE Liquid drink bases (including concentrates and home-made preparations) C 192 mg 1,925 mg
A03GF Powdered drink bases C 192 mg 1,925 mg
A03RQ Products for non-standard diets, food imitates and food supplements H
A03RR Food for particular diets H
A03RS Food for weight reduction M
A03RT Total daily diet replacement for weight reduction C 963 mg 1,925 mg
A03RV Single meal replacement for weight reduction C 320 mg 1,925 mg
A03RX Food for sporting people M
A03RY Carbohydrate-rich energy food products for sports people C 320 mg 1,925 mg
A03RZ Carbohydrate-electrolyte solutions for sports people C 192 mg/L 385 mg/L
A03SB Micronutrients supplement for sports people C 963 mg 1,925 mg
A03SD Dietary foods for special medical purposes M
A03SE Nutritionally complete formulae C 963 mg 1,925 mg
A03SF Nutritionally incomplete formulae C 320 mg 1,925 mg
A03SH Oral rehydration products C 192 mg/L 385 mg/L
A03SJ Food supplements and similar preparations M
A03TC Mixed supplements/formulations C 100 g 900 g
A03SM Mineral only supplements C 200 g 1,000 g
A03SN Combination of vitamin and mineral only supplements C 100 g 1,000 g
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A046L Major isolated ingredients, additives, ﬂavours, baking and processing aids H
A0EVD Isolated proteins and other protein products M
A02PR Milk protein C 320 mg 1,925 mg
A02PS Whey protein C 320 mg 1,925 mg
A01BG Soya proteins C 320 mg 1,925 mg
A0F5E Gelatine C 320 mg 1,925 mg
A0ETM Starches M
A002R Maize starch C 320 mg 1,925 mg
A003A Oat starch C 320 mg 1,925 mg
A003G Rice starch C 320 mg 1,925 mg
A003R Rye starch C 320 mg 1,925 mg
A004M Wheat starch C 320 mg 1,925 mg
A011F Potato starch C 320 mg 1,925 mg
A011J Tapioca starch C 320 mg 1,925 mg
A0DPT Maltodextrins and similar M
A0BSL Maltodextrin C 320 mg 1,925 mg
A0BSK Dextrin C 320 mg 1,925 mg
A04QR Other regulated additives H
A048C Acidity regulator C 320 mg 1,925 mg
A0F0S Other ingredients H
A0EVF Chemical elements M
A0EXF Magnesium C 100 g 1 kg
DMM: di-magnesium malate.
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